Post-transplant Lymphoproliferative Disorder
Article Sidebar
Main Article Content
Abstract
Post-transplant lymphoproliferative disorder (PTLD), is a common malignancy found in patients who have undergone organ transplantation, following non-melanoma skin cancer. In Thailand, the majority of patients who have received organ transplants and subsequently passed away often succumb to infections, followed by cardiovascular diseases and cancer. PTLD is one of the malignancy contributing to these fatalities. Assessing the risk, monitoring for Epstein-Barr virus infection, reducing immunosuppressive medication, and administering chemotherapy are methods to alleviate and treat PTLD. This allows transplant recipients to use their transplanted organs for a longer period, accompanied by an improved quality of life.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under CC BY-NC-ND 4.0 license, which allows for non-commercial reuse of the published paper as long as the published paper is fully attributed. Anyone can share (copy and redistribute) the material in any medium or format without having to ask permission from the author or the Nephrology Society of Thailand.
References
Kaballo MA, Canney M, O’Kelly P, Williams Y, O’Seaghdha CM, Conlon PJ. A comparative analysis of survival of patients on dialysis and after kidney transplantation. Clin Kidney J 2018;11(3):389-93. doi: 10.1093/ckj/sfx117.
สมาคมปลูกถ่ายอวัยวะแห่งประเทศไทย. รายงานข้อมูลการปลูกถ่ายอวัยวะประจำปี พ.ศ. 2565. 2565:17-41.
Laowalert S, Prasongsook N, Ativitasvas T, Liwlompaisan W, Thanak P, Techawathanawanna N, et al. INCIDENCE AND SURVIVAL OF MALIGNANCY FOLLOWING KIDNEY TRANSPLANTATION AT A SINGLE CENTER IN THAILAND. Transplantation 2020;104(S3):S415. doi: 10.1097/01.tp.0000700720.77351.38.
Caillard S, Lamy FX, Quelen C, Dantal J, Lebranchu Y, Lang P, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012;12(3):682-93. doi: 10.1111/j.1600-6143.2011.03896.x.
Faull RJ, Hollett P, McDonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005;80(2):193-7. doi: 10.1097/01.tp.0000165098.49658.f3.
Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4(2):222-30. doi: 10.1046/j.1600-6143.2003.00325.x.
Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998;338(20):1413-21. doi: 10.1056/nejm199805143382003.
Craig FE, Johnson LR, Harvey SA, Nalesnik MA, Luo JH, Bhattacharya SD, et al. Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn Mol Pathol 2007;16(3):158-68. doi: 10.1097/PDM. 0b013e31804f54a9.
Srivatsa K, Taj M. Childhood post-transplant lymphoproliferative disorder. Paediatrics and Child Health 2021;31(3):95-101. doi: https://doi.org/10.1016/j.paed.2020.12.001.
Allen UD, Preiksaitis JK, the ASTIDCoP. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation 2019;33(9):e13652. doi: https://doi.org/10.1111/ctr.13652.
Dharnidharka VR, Lamb KE, Gregg JA, Meier-Kriesche HU. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States. Am J Transplant 2012;12(4):976-83. doi: 10.1111/j.1600-6143.2011.03893.x.
Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995;20(5):1346-53. doi: 10.1093/clinids/20.5.1346.
Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3(2):70-8. doi: 10.1034/j.1399-3062.2001.003002070.x.
Sprangers B, Riella LV, Dierickx D. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review. Am J Kidney Dis 2021;78(2):272-81. doi: 10.1053/j.ajkd.2021.01.015.
Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, et al. Three-year outcomes from BENEFITEXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012;12(3):630-9. doi: 10.1111/j.1600-6143.2011.03914.x.
Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133(1):173-92.
Penn I, Port G. Central Nervous System Lymphomas In Organ Allograft Recipients. Transplantation 1995;59(2).
Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998;16(6):2052-9. doi: 10.1200/jco.1998.16.6.2052.
สมาคมปลูกถ่ายอวัยวะแห่งประเทศไทย. แนวทางการประเมินผู้รับบริจาคไต (Kidney transplant candidate/Recipient) เพื่อรอรับการปลูกถ่ายไตในผู้ป่วยไตวายเรื้อรังระยะสุดท้าย. 2020 (ตุลาคม2563).
Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DLJ. Quantitative Oropharyngeal Epstein-Barr Virus Shedding in Renal and Cardiac Transplant Recipients: Relationship to Immunosuppressive Therapy, Serologic Responses, and the Risk of Posttransplant Lymphoproliferative Disorder. The Journal of Infectious Diseases 1992;166(5):986-94. doi: 10.1093/infdis/166.5.986.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32(27):3059-68. doi: 10.1200/jco.2013.54.8800.
Bianchi E, Pascual M, Nicod M, Delaloye AB, Duchosal MA. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease. Transplantation 2008;85(5):707-12. doi: 10.1097/TP.0b013e3181661676.
Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, et al. End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry. Transplantation 2018;102(5):868-75. doi: 10.1097/tp.0000000000002006.
Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, 4th edition. Lyon 2017.
Dierickx D, Habermann TM. Post-Transplantation Lymphoproliferative Disorders in Adults. New England Journal of Medicine 2018;378(6):549-62. doi: 10.1056/NEJMra1702693.
AlDabbagh MA, Gitman MR, Kumar D, Humar A, Rotstein C, Husain S. The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review. Am J Transplant 2017;17(3):770-81. doi: 10.1111/ajt.14020.
Humar A, Hébert D, Davies HD, Humar A, Stephens D, O’Doherty B, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006;81(6):856-61. doi: 10.1097/01.tp.0000202724.07714.a2.
Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5(9):2222-8. doi: 10.1111/j.1600-6143.2005.01002.x.
Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77(4):299-311. doi: 10.1038/ki.2009.377.
Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, et al. Reduction of immunosuppression as nitial therapy for posttransplantation lymphoproliferative disorder( ). Am J Transplant 2011;11(2):336-47. doi: 10.1111/j.1600-6143.2010.03387.x.
Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010;149(5):693-705. doi: 10.1111/j.1365-2141.2010.08160.x.
Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012;13(2):196-206. doi: 10.1016/s1470-2045(11)70300-x.
Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. The Lancet Haematology 2016;3(5):e217-e27. doi: 10.1016/S2352-3026(16)00036-3.
network Ncc. Post transplant lymphoproliferative disorder (PTLD). 2015(2):2-4.
A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329(14):987-94. doi: 10.1056/nejm199309303291402.
Johnson SR, Cherikh WS, Kauffman HM, Pavlakis M, Hanto DW. Retransplantation after post-transplant lymphoproliferative disorders: an OPTN/UNOS database analysis. Am J Transplant 2006;6(11):2743-9. doi: 10.1111/j.1600-6143.2006.01543.x.
